CCS Integrated Cases

CCS case: routine preventive visit with multiple screenings

Clinical Overview and When to Suspect Preventive Care Gaps

— Preventive visits are the highest-yield CCS case for testing USPSTF grade A/B recommendations, ACIP schedules, and shared decision-making (SDM) items

— Examinees lose points by ordering tests that are not recommended (e.g., routine PSA without SDM, screening EKG, vitamin D, CBC "just because") or by skipping indicated screens

— Screening: cancer, cardiovascular, metabolic, infectious, mental health, osteoporosis, AAA

— Immunizations: age-, condition-, and risk-based per ACIP

— Behavioral counseling: tobacco, alcohol/unhealthy drug use, diet/activity, safe sex, intimate partner violence, fall prevention

— Chemoprevention: statin for primary prevention, low-dose aspirin (narrow indications), folic acid in reproductive-age women

— Risk assessment: family history update, social history, ASCVD risk calculator, depression/anxiety screen

— New patient establishing care

— Patient returning after >1 year without preventive services

— Hospital discharge follow-up where chronic care has displaced prevention

— Transitions: turning 40, 45, 50, 65 — each triggers new screens

Scenario framing: A 52-year-old establishes care for an annual wellness visit. No acute complaints. The CCS task is to convert "feels fine" into a structured, age- and risk-appropriate menu of screening, immunization, counseling, and chemoprevention decisions.

Why this matters on Step 3:

Framework to memorize — the "5 buckets":

When to suspect a "preventive care gap":

CCS pearl: On the simulated office case, the very first orders should be vital signs, height/weight/BMI, brief history, and a focused physical, then build the prevention menu. Avoid ordering imaging or specialty referrals before establishing risk. The clock advances in weeks-to-months for outpatient cases, so order screens, then advance the clock to results, rather than stacking everything at once.

Board pearl: USPSTF grade A and B = "offer/provide"; grade C = SDM in selected patients; grade D = do not offer; grade I = insufficient evidence (don't order on the exam).

Presentation Patterns and Key History

— Past medical/surgical history: chronic conditions modify screening (e.g., diabetes → annual eye, foot, urine albumin/Cr; prior colon adenoma → shorter colonoscopy interval)

— Medications and allergies: identify polypharmacy, anticholinergics in elderly, statin eligibility, contraception

— Family history: first-degree relative with colon cancer <60 → colonoscopy at age 40 or 10 years before index case; BRCA-suggestive pedigree → genetic counseling referral; premature CAD (<55 M, <65 F) → adjust ASCVD discussion

— Social history: tobacco (pack-years for lung cancer screen), alcohol (AUDIT-C), drug use, sexual history (5 P's), occupation, exercise, diet, seatbelt/helmet use, firearm access

— Reproductive: LMP, contraception, pregnancy intention, last Pap, mammogram

— Immunization history: review record before ordering vaccines

— Functional/ADL status in elderly: falls in last year, hearing, vision, continence, cognition

— Age 45 → start colorectal cancer (CRC) screening, consider type 2 diabetes screening

— Age 50–80 + ≥20 pack-years + smoking or quit <15 yr → low-dose CT lung screen

— Age 65–75 male ever-smoker → one-time AAA ultrasound

— Postmenopausal woman ≥65 → DEXA

— BMI ≥30 → intensive behavioral counseling for weight

Typical CCS stem: "Patient presents for routine health maintenance." Sometimes embedded inside a chronic disease follow-up ("here for diabetes check") — you are still expected to address overdue prevention.

Required history elements (order these as part of the interview):

Key triggers in the stem:

Key distinction: "Annual physical" is a lay term; the billable encounter is the Medicare Annual Wellness Visit (AWV) or commercial preventive visit. AWV is not a head-to-toe exam — it is a health risk assessment + prevention plan. Confusing these costs points when the stem highlights billing/coding.

Step 3 management: Always document tobacco status and offer cessation at every visit — it is the single most cost-effective preventive intervention and a frequent CCS scoring item.

Physical Exam Findings and Office Measurements

— Blood pressure (both arms on first visit; repeat if elevated, confirm out-of-office before diagnosing HTN per USPSTF/ACC)

— Height, weight, BMI; waist circumference if BMI 25–34.9

— Heart rate, respiratory rate; temperature if symptomatic

— Visual acuity in adults ≥65 (USPSTF: insufficient evidence in general adults but reasonable in elderly)

— Skin: total-body skin exam is grade I (insufficient evidence) for routine screening but reasonable in high-risk (fair skin, prior skin cancer, immunosuppression, tanning bed use)

— Cardiovascular: auscultation; check for AAA pulsation in eligible men; carotid bruit screening = grade D in asymptomatic adults

— Breast: clinical breast exam not required by USPSTF; ACS does not recommend; discuss with patient

— Pelvic exam: only needed for indicated Pap/STI testing; routine bimanual in asymptomatic women is not recommended

— Testicular/prostate: routine testicular exam = grade D; DRE alone for prostate cancer screening = not recommended

— Foot exam in diabetics: annual monofilament, pulses, skin integrity

— Cognitive screen ≥65: Medicare AWV requires structured assessment (Mini-Cog acceptable) — USPSTF grade I, but Medicare-required

— Depression screen: PHQ-2 → PHQ-9 if positive (grade B all adults including pregnancy/postpartum)

— Falls in ≥65: Timed Up-and-Go; ask about falls in past year

Required vitals and measurements (order on arrival):

Focused exam by age/risk:

Hemodynamic note: BP ≥130/80 on average of properly measured readings → stage 1 HTN per ACC/AHA. Confirm with ambulatory or home BP monitoring before pharmacotherapy — a high-yield CCS step.

Board pearl: Do not order routine resting ECG, stress testing, carotid ultrasound, CXR, urinalysis, or CBC in asymptomatic average-risk adults — these are USPSTF grade D or I and lose points.

Step 3 management: If office BP is 150/95, the correct next step is out-of-office BP monitoring (HBPM or ABPM), not immediate antihypertensive initiation, unless markedly elevated (≥180/120) or end-organ damage is present.

Diagnostic Workup — Core Screening Labs and Studies

— Lipid panel (fasting or non-fasting): screen adults 40–75 for ASCVD risk; earlier if family history or risk factors

— Hemoglobin A1c or fasting glucose: USPSTF recommends screening adults 35–70 with overweight/obesity (grade B); ADA suggests all adults ≥35

— HIV: one-time screen ages 15–65 (grade A); annually if high risk

— Hepatitis C: one-time screen all adults 18–79 (grade B)

— Hepatitis B: screen all adults ≥18 at least once (USPSTF 2023 update, grade B)

— Syphilis, gonorrhea, chlamydia: risk-based; women <25 and sexually active → annual GC/CT; MSM and pregnant women have specific protocols

— TB (IGRA or PPD): only if risk factors (foreign-born from high-prevalence area, healthcare worker, incarcerated, immunocompromised)

— CRC: start age 45, stop 75 (SDM 76–85). Options: colonoscopy q10y, FIT annually, FIT-DNA (Cologuard) q1–3y, flex sig q5y, CT colonography q5y

— Cervical: 21–29 cytology q3y; 30–65 cytology q3y OR HPV q5y OR co-test q5y; stop at 65 if adequate prior negatives

— Breast: USPSTF 2024 — biennial mammography ages 40–74 (grade B); ACS allows annual 40–54

— Lung: annual LDCT ages 50–80, ≥20 pack-years, current smoker or quit <15 yr

— Prostate: SDM ages 55–69 (grade C); discuss but do not auto-order PSA

— AAA: one-time U/S men 65–75 who ever smoked (grade B)

Order set for a healthy 50-year-old at the CCS terminal (advance clock to results):

Cancer screening to order:

Bone health: DEXA in women ≥65, or postmenopausal <65 with FRAX risk ≥9.3%

CCS pearl: Order labs and screening studies, then click "advance clock" to 2 weeks for results. Do not order both colonoscopy and FIT — that's redundant and signals weak test discipline.

Key distinction: USPSTF says screen for diabetes 35–70 in overweight/obese; ADA says screen everyone ≥35. On Step 3, default to USPSTF unless ADA is explicitly cited.

Diagnostic Workup — Risk-Based and Confirmatory Studies

— ASCVD risk calculator (Pooled Cohort Equations): use 10-year risk to guide statin SDM in adults 40–75 with ≥1 risk factor and LDL 70–189

— Coronary artery calcium (CAC) score: optional tie-breaker when 10-year ASCVD risk is borderline (5–<7.5%) or intermediate (7.5–<20%) and statin decision is uncertain

— Genetic counseling/BRCA testing: women with family or personal history suggesting BRCA1/2 risk — use a screening tool (e.g., FHS-7, BRCAPRO); USPSTF grade B for counseling referral, not direct testing

— Lynch syndrome evaluation: ≥1 first-degree relative with CRC <50, or pedigree fitting Amsterdam/Bethesda criteria

— Osteoporosis confirmation: if DEXA T-score ≤ –2.5 or –1.0 to –2.5 with FRAX ≥3% hip / ≥20% major fracture risk → treat

— Pre-diabetes (A1c 5.7–6.4%): confirm with repeat, then enroll in DPP (Diabetes Prevention Program) and consider metformin if BMI ≥35, age <60, or prior GDM

— Hypertension confirmation: 7-day HBPM average or 24-hr ABPM before labeling and treating

— Routine EKG, stress test, echo in asymptomatic adults

— Carotid duplex in asymptomatic

— Vitamin D level screening

— TSH in asymptomatic non-pregnant adults

— CA-125, CEA, or "tumor marker panels"

— Whole-body imaging, executive physicals

— Routine pelvic exam in asymptomatic non-pregnant women

— Immigrants/refugees: latent TB testing, HBV/HCV/HIV, schistosomiasis/strongyloides if endemic exposure

— MSM: extragenital GC/CT (pharyngeal, rectal), HIV q3–12 mo, HBV/HAV vaccination, HIV PrEP discussion

— Trans patients: screen organs present (e.g., cervix if retained, breast tissue per hormone exposure)

Trigger-based additional testing — only if the stem provides the trigger:

Studies you should NOT order routinely (grade D / I — lose points):

Special situations:

Step 3 management: When you face a borderline statin decision, CAC = 0 in a non-smoker non-diabetic ≥55 supports deferring statin; CAC ≥100 or ≥75th percentile supports initiating statin.

Board pearl: Routine vitamin D screening is not recommended by USPSTF (grade I) — ordering it on CCS is a classic distractor.

Risk Stratification and Prevention Plan Logic

— Step 1: Calculate ASCVD 10-yr risk using Pooled Cohort Equations for adults 40–75

– <5%: lifestyle counseling

– 5–<7.5% (borderline): SDM, consider risk enhancers; CAC if uncertain

– 7.5–<20% (intermediate): moderate-intensity statin + lifestyle

– ≥20% (high): high-intensity statin + lifestyle

— Step 2: Diabetes status

– A1c <5.7: rescreen q3y

– 5.7–6.4 (prediabetes): DPP referral, lifestyle, ± metformin

– ≥6.5 or fasting ≥126 ×2: type 2 diabetes — initiate metformin + lifestyle, address comorbidities

— Step 3: BP

– <120/80 ideal; 120–129/<80 elevated → lifestyle

– 130–139/80–89 stage 1: lifestyle; pharmacotherapy if ASCVD ≥10% or DM/CKD

– ≥140/90 stage 2: lifestyle + pharmacotherapy

— Step 4: BMI

– ≥30 or ≥25 with comorbidity: intensive behavioral counseling (grade B); consider pharmacotherapy (GLP-1 RA, semaglutide/tirzepatide) or bariatric surgery if BMI ≥40 or ≥35 with comorbidity

— Step 5: Tobacco/alcohol/drugs

– 5 A's (Ask, Advise, Assess, Assist, Arrange); offer varenicline or combination NRT as first-line

– AUDIT-C ≥4 men/≥3 women: brief intervention

— Step 6: Mental health

– PHQ-9 ≥10: treat depression (SSRI + therapy)

– GAD-7, suicide risk, IPV screen

— Adults 40–59 with ≥10% 10-yr ASCVD risk: individualized SDM (grade C)

— Adults ≥60: do not initiate aspirin for primary prevention (grade D)

Step-by-step CCS workflow once history/exam/labs return (advance clock to "office visit, results review"):

Aspirin for primary prevention (USPSTF 2022, grade C/D):

CCS pearl: When the clock allows, schedule a follow-up visit in 3 months to recheck BP, A1c response, weight, and adherence rather than stacking interventions in one encounter — mirrors real ambulatory practice and scores well.

Board pearl: Prevention "risk stratification" on Step 3 is mostly age + risk factor + USPSTF grade — memorize the grade letters.

Pharmacotherapy and Chemoprevention — First-Line Choices

— Moderate-intensity: atorvastatin 10–20 mg or rosuvastatin 5–10 mg

— High-intensity: atorvastatin 40–80 mg or rosuvastatin 20–40 mg

— Baseline lipid panel, ALT; recheck lipids in 4–12 weeks, then 3–12 months; no routine LFT monitoring unless symptomatic

— Non-Black, non-DM: thiazide, ACEi/ARB, or CCB

— Black without CKD: thiazide or CCB first-line

— CKD or DM with albuminuria: ACEi or ARB

— Varenicline 0.5 mg daily ×3 d → 0.5 mg BID ×4 d → 1 mg BID ×12 wk (most effective monotherapy)

— Combination NRT (patch + lozenge/gum)

— Bupropion SR 150 mg daily ×3 d → BID; avoid in seizure disorder

— Influenza annually ≥6 mo

— COVID-19 updated annually

— Tdap once, then Td/Tdap q10y; Tdap each pregnancy 27–36 wk

— HPV through age 26 (SDM 27–45); 2 doses if <15 at start, 3 if ≥15

— Zoster (Shingrix) 2 doses ≥50, and ≥19 if immunocompromised

— Pneumococcal: PCV20 alone OR PCV15 + PPSV23 — all adults ≥65 and 19–64 with risk

— RSV: ≥75 universal; 60–74 with risk; pregnancy 32–36 wk seasonal

— Hep B: all adults 19–59; ≥60 with risk

Statins (primary prevention, ASCVD 40–75):

Antihypertensives (stage 2 or stage 1 with ASCVD ≥10%/DM/CKD):

Metformin for prediabetes if BMI ≥35, age <60, or prior GDM (off-label but ADA-endorsed): start 500 mg daily, titrate to 1000 mg BID

Aspirin 81 mg: only after SDM in 40–59 with ≥10% ASCVD and low bleed risk; not in ≥60 for primary prevention

Folic acid 400–800 mcg/day: all women planning or capable of pregnancy (grade A); 4 mg if prior NTD

Tamoxifen/raloxifene/AIs: chemoprevention in women ≥35 at increased breast cancer risk and low risk of adverse effects (grade B) — SDM

HIV PrEP: emtricitabine/tenofovir (oral) or cabotegravir LA for adults at risk (grade A); baseline HIV, HBV, renal function

Tobacco cessation:

Vaccines as "pharmacotherapy" (ACIP 2024–25 highlights):

CCS pearl: Always order baseline labs before statin (lipids, ALT, A1c) and document SDM for aspirin and PSA in the note.

Counseling Interventions and Behavioral Chemoprevention

— Healthy diet + physical activity in adults with CV risk factors (grade B); in adults without risk factors, grade C — SDM

— Intensive multicomponent behavioral interventions for obesity (BMI ≥30): ≥12 sessions in 1 year

— Tobacco cessation counseling + pharmacotherapy at every visit

— Unhealthy alcohol use: screen + brief behavioral counseling (grade B)

— STI prevention counseling in sexually active adolescents and adults at risk (grade B)

— Skin cancer behavioral counseling in fair-skinned 6 mo–24 yr (grade B); 24–65 with risk factors (grade C)

— Falls prevention in ≥65 with increased risk: exercise interventions (grade B); multifactorial assessment (grade C)

— Interpersonal violence screening in women of reproductive age (grade B)

— Contraception counseling for all reproductive-age women; offer LARC as first-line option

— Preconception counseling: folic acid, optimize chronic disease (A1c <6.5%, BP control), review teratogenic meds (ACEi, statins, warfarin, valproate, isotretinoin, methotrexate)

— STI: condoms, PrEP eligibility, partner notification

— Seat belts, helmets, smoke detectors, CO detectors

— Firearm safety counseling — locked, unloaded, ammunition stored separately — particularly in households with children, dementia, or suicidality

— Driving safety in elderly with cognitive impairment

— Screen for housing, food insecurity, transportation (PRAPARE or similar)

— Sleep hygiene, screening for OSA if risk factors (STOP-BANG)

— Offer to all adults, especially ≥65 or with serious illness

— Designate healthcare proxy, complete advance directive/POLST as appropriate — billable under Medicare AWV

High-intensity behavioral counseling (USPSTF grade B — order the referral):

Reproductive/sexual health:

Injury prevention:

Sleep, stress, social determinants:

Advance care planning:

Step 3 management: When the case stem mentions a firearm in the home plus depression or dementia, the highest-yield action is direct firearm safety counseling and means restriction, not just "refer to psychiatry."

Board pearl: Behavioral counseling referrals count as orders on CCS — place them explicitly (e.g., "refer: tobacco cessation program," "refer: registered dietitian").

Special Populations — Elderly and Renal/Hepatic Considerations

— AAA ultrasound once in men 65–75 who ever smoked

— Osteoporosis: DEXA in all women ≥65; men ≥70 or younger with risk (ACR/Endocrine Society — USPSTF says insufficient for men)

— Falls: ask about falls in past year, gait/balance; exercise referral if at risk; vitamin D for fall prevention = grade D in community-dwelling adults

— Cognitive impairment screening: USPSTF grade I, but Medicare AWV requires structured assessment

— Hearing and vision: screen and refer; correctable deficits reduce falls and isolation

— Polypharmacy review: apply Beers criteria — avoid benzodiazepines, anticholinergics (diphenhydramine, oxybutynin), long-acting sulfonylureas, NSAIDs

— Deprescribing: statins in limited life expectancy, tight glycemic targets (A1c <7%) often loosened to <7.5–8% in frail elderly

— CRC: stop at 75 routinely; SDM 76–85; stop ≥86

— Cervical: stop at 65 with adequate prior negative screening

— Breast: USPSTF stops at 74; ACS allows continuation if life expectancy ≥10 years

— Prostate: do not screen ≥70

— Lung LDCT: stop at 80, or when life expectancy limits benefit, or quit >15 years

— Avoid NSAIDs, adjust metformin (contraindicated <30, caution 30–45)

— ACEi/ARB still preferred in diabetic CKD with albuminuria; monitor K and Cr 1–2 weeks after start (≤30% Cr rise acceptable)

— SGLT2 inhibitors (empagliflozin, dapagliflozin) reduce CKD progression; can initiate down to eGFR 20

— Adjust gabapentin, allopurinol, DOACs

— Statins generally safe in stable chronic liver disease, including NAFLD; avoid only in decompensated cirrhosis or acute liver failure

— Acetaminophen ≤2 g/day in cirrhosis; avoid NSAIDs

— HCC surveillance: U/S ± AFP q6 mo in cirrhosis or chronic HBV with risk

Adults ≥65 — additional or modified screens:

When to STOP screening:

Renal impairment (eGFR <60):

Hepatic impairment:

CCS pearl: In an 82-year-old well-controlled diabetic, do not order a screening colonoscopy — score points by recognizing limited life expectancy as a stop-screening trigger.

Board pearl: "Number needed to screen" rises with age; harms of screening (false positives, overdiagnosis) become dominant — Step 3 loves this concept.

Special Populations — Pregnancy, Pediatrics-Adjacent, and Demographic Subgroups

— First visit: CBC, blood type/Rh + antibody screen, RPR/syphilis, HIV, HBsAg, HCV (every pregnancy per CDC 2021), rubella IgG, varicella, urine culture, Pap if due, GC/CT if <25 or risk

— Repeat HIV and syphilis in third trimester in high-prevalence areas

— GBS culture 36 0/7–37 6/7 weeks

— GDM screen 24–28 weeks (1-hour 50 g GCT)

— Aspirin 81 mg daily from 12 wk for preeclampsia prevention if ≥1 high-risk or ≥2 moderate-risk factors

— Vaccines in pregnancy: Tdap each pregnancy 27–36 wk; influenza any trimester; COVID-19; RSV (maternal RSVpreF) 32–36 wk Sept–Jan; avoid live (MMR, varicella, LAIV)

— Folic acid 400–800 mcg preconception and through first trimester

— Depression/IPV screening at intake, each trimester, and postpartum

— Contraception, mood, breastfeeding, GDM → 75 g OGTT 4–12 wk postpartum

— Cardiovascular risk: preeclampsia/GDM history → lifelong elevated ASCVD risk; intensify lifestyle, statins per risk

— HEEADSSS interview, contraception, HPV catch-up through 26, meningococcal B SDM 16–23, mental health screen, safe driving, substance use

— Black adults: higher ASCVD, CKD, and breast cancer mortality — emphasize early BP control, ACEi caution for angioedema; CCB/thiazide preferred

— Asian populations: lower BMI threshold for diabetes screening (≥23)

— LGBTQ+ patients: screen organs present; ask about hormone therapy; HIV PrEP for MSM/TGW at risk; mental health

— Veterans: PTSD screen, military exposures (burn pits, Agent Orange → specific cancer surveillance)

Pregnant patients (prenatal preventive bundle):

Postpartum visit (within 3 weeks, then comprehensive by 12 weeks):

Adolescents/young adults (18–21 transitioning to adult care):

Demographic subgroups:

Step 3 management: A pregnant woman with chronic HTN on lisinopril — stop ACEi/ARB immediately, switch to labetalol, nifedipine ER, or methyldopa.

Board pearl: Aspirin 81 mg from 12 weeks for preeclampsia prevention is one of the most tested USPSTF grade B prenatal items.

Complications and Adverse Outcomes of Screening Itself

— PSA screening: ~20–50% of screen-detected prostate cancers are overdiagnosed; harms include incontinence, ED from treatment — drives the grade C, SDM-only recommendation

— Mammography: false positives (~10% per round), biopsy-related anxiety, overdiagnosis of DCIS that would never progress

— Thyroid cancer screening (grade D): detects indolent papillary cancers — harm > benefit

— Ovarian cancer screening with CA-125/TVUS (grade D): unnecessary oophorectomies

— Colonoscopy: perforation ~4/10,000, bleeding ~8/10,000, sedation risks

— LDCT lung screen: 12–14% false-positive rate; incidental findings; radiation

— CT colonography: extracolonic findings cascade

— Aspirin: GI bleed, ICH — risk approaches benefit in older adults, driving 2022 update

— Statins: myalgia (mostly nocebo), small T2DM risk increase, rare rhabdomyolysis; do not stop for asymptomatic CK or LFT bumps <3× ULN

— Antihypertensives: orthostasis, falls in elderly, electrolyte disturbances

— Counsel on common reactions (sore arm, fever 24–48 hr); rare anaphylaxis

— Specific: Shingrix → reactogenic; HPV → syncope post-injection (observe 15 min); LAIV avoided in immunocompromised/pregnancy

— Incidental thyroid nodules, adrenal "incidentalomas," pulmonary nodules trigger surveillance imaging, anxiety, biopsies

— Underscreening in underserved populations (transportation, insurance) drives mortality disparities — counterbalance to "overscreening" critique

Overdiagnosis and overtreatment:

Procedure-related harms:

Medication harms in primary prevention:

Vaccine adverse events:

Cascade-of-care harms:

Equity harms:

CCS pearl: When the simulator flags a false-positive screening result (e.g., positive FIT), the correct next step is colonoscopy, not repeat FIT — points are awarded for following the algorithm, not for "reassurance."

Board pearl: Step 3 frequently tests NNT/NNH and lead-time / length-time / overdiagnosis biases in screening — recognize them in stems describing improved "5-year survival" without mortality benefit.

When to Escalate — Referral, Specialty Consult, and Triage from the Preventive Visit

— BP ≥180/120 with symptoms (chest pain, vision change, headache, neuro deficit) → hypertensive emergency, send to ED

— Suicidal ideation with plan/intent → emergent psychiatric evaluation; do not allow departure unaccompanied

— Active IPV with immediate safety threat → safety planning, social work, shelter resources

— New focal neurologic deficit, severe chest pain, or signs of acute illness uncovered during "wellness" visit → reframe as acute care

— Suspicious breast mass → diagnostic mammogram + US within 1–2 weeks; breast surgery referral

— Hematochezia, iron deficiency anemia, weight loss → GI for diagnostic colonoscopy (not screening)

— Pulmonary nodule on LDCT per Lung-RADS 4 → pulmonology/thoracic surgery

— Concerning skin lesion (ABCDE) → dermatology

— Newly elevated A1c ≥10% or symptomatic hyperglycemia → endocrinology / start insulin

— Genetic counseling: BRCA/Lynch pedigree

— Cardiology: known CAD optimization or borderline-risk CAC decision

— Nephrology: eGFR <30, rapid decline, or significant proteinuria (UACR >300)

— Dietitian / DPP: prediabetes, obesity

— Behavioral health: PHQ-9 ≥15, comorbid SUD

— Sleep medicine: STOP-BANG ≥3 with symptoms

— Care manager for poorly controlled chronic disease

— Pharmacist consult for polypharmacy in elderly

— Social work for transportation, food, housing insecurity

Same-day urgent action (do not let the patient leave without):

Same-week or expedited referrals:

Routine (weeks to months) referrals:

Health-systems-level escalations:

CCS pearl: Place referrals explicitly ("consult: cardiology," "refer: genetic counseling") rather than vague "outpatient follow-up." The grader credits named consultants.

Step 3 management: A 58-year-old at her wellness visit endorses 2 months of melena — stop the preventive workflow, order CBC, type/screen, and same-day GI consult; defer routine screenings until the acute issue is resolved.

Key Differentials — Other Visit Types in Ambulatory Care

— Medicare Annual Wellness Visit (AWV): G0438 (initial) / G0439 (subsequent). Includes HRA, cognitive assessment, fall risk, depression screen, advance care planning. Does not include a comprehensive physical exam. No copay.

— Initial Preventive Physical Exam (IPPE / "Welcome to Medicare"): G0402, within first 12 months of Part B. Includes AAA referral if eligible, EKG (one-time, optional).

— Commercial preventive visit (CPT 99381–99397): comprehensive age-appropriate exam + counseling + ordering screens. No copay under ACA for grade A/B services.

— Chronic disease follow-up (99213/99214): problem-oriented, billed separately; can be combined with AWV using modifier 25 if both services delivered

— Transitional Care Management (99495/99496): post-discharge within 7 or 14 days

— Chronic Care Management (99490): ≥20 min/month, ≥2 chronic conditions

— Stems often hide a billing/coding question inside a clinical vignette ("which visit type captures this work?")

— Confusing AWV with a physical leads to the wrong order set

— Pre-op evaluation: not preventive — focus on perioperative risk (RCRI, functional capacity, condition-specific testing). Do not order screening colonoscopy as part of pre-op

— Sports/camp/DOT physical: targeted clearance, not full prevention

— Disability/FMLA paperwork visit: documentation-focused

— Insurance/employment physical: not the place to address SDM-heavy items

Within the "wellness/prevention" family, distinguish:

Why this matters for Step 3:

Other "screening look-alikes":

Key distinction: Pre-op visits screen for perioperative risk, AWVs screen for lifetime risk. Conflating them causes inappropriate cardiac testing pre-op (e.g., stress test in low-risk patient with good functional capacity = wrong answer).

Board pearl: Under the ACA, USPSTF grade A and B services + ACIP-recommended vaccines + HRSA women's preventive services must be covered without cost-sharing in non-grandfathered plans. Knowing this addresses access-related stem prompts.

Key Differentials — Symptom-Driven vs Screening Workups

— Colonoscopy for hematochezia → diagnostic, not "screening"; no age cutoff; cost-share applies

— Mammogram for palpable mass → diagnostic mammogram + targeted U/S; biopsy if BI-RADS 4/5

— PSA in a man with bone pain and weight loss → diagnostic workup for metastatic prostate cancer, not "shared decision-making"

— A1c in a polyuric, polydipsic patient → diagnostic for new diabetes; treat regardless of USPSTF age cutoff

— Chest CT for hemoptysis in a smoker → diagnostic; do not call it lung screening

— Iron-deficiency anemia in a postmenopausal woman → not "screening" — workup for GI malignancy

— Microscopic hematuria → AUA risk-stratified workup, not "routine UA follow-up"

— Incidental adrenal mass on imaging done for another reason → biochemical workup (1-mg dex suppression, plasma metanephrines, aldo/renin) + size-based follow-up

— Newly elevated BP ≥180/110 with end-organ damage → hypertensive emergency

— A1c ≥10% with symptoms → initiate insulin, not just lifestyle

— Severe depression with SI → safety + treatment before "PHQ-9 follow-up"

— Stage 1 HTN without ASCVD risk → lifestyle only, not pharmacotherapy

— Prediabetes → DPP and lifestyle, metformin only if specific criteria

— Obesity without comorbidity → behavioral counseling first; pharmacotherapy/surgery after failure or comorbidity present

The cardinal rule: A "screening" test is performed in an asymptomatic patient. The moment symptoms appear, the same test becomes diagnostic — with different indications, intervals, insurance coverage, and follow-up algorithms.

High-yield examples:

Conditions that mimic "screening findings":

Conditions that look like prevention but require treatment first:

Counseling vs. treatment confusion:

CCS pearl: When the patient's "wellness visit" stem includes a red-flag symptom (melena, breast mass, hemoptysis, chest pain, suicidal ideation), pivot immediately to diagnostic workup. Continuing the preventive checklist while ignoring the red flag is a major scoring loss.

Board pearl: USPSTF recommendations apply only to asymptomatic adults. Memorize this — it disarms half the screening distractors.

Long-Term Plan, Chronic Care Coordination, and "Discharge" Medications

— Each identified risk → an explicit plan + interval

— Document shared decisions (PSA, aspirin, LDCT) in the chart

— Atorvastatin 20 mg nightly for ASCVD primary prevention (intermediate risk)

— Lisinopril 10 mg daily for stage 2 HTN (non-Black) — recheck BMP in 1–2 weeks

— Metformin 500 mg with dinner, titrate weekly, for new T2DM or eligible prediabetes

— Folic acid 400 mcg daily in reproductive-age women

— Vitamin D / calcium only if osteoporosis or documented deficiency — not universal

— Bisphosphonate (alendronate 70 mg weekly) for T-score ≤ –2.5 or FRAX-qualifying osteopenia; ensure adequate calcium/vitamin D, dental clearance

— HIV PrEP with baseline labs

— Schedule HPV, Hep B, Shingrix, pneumococcal series with specific return dates

— Document lot numbers (CCS-style precision)

— Refer to RD, DPP, tobacco quitline (1-800-QUIT-NOW), behavioral health

— Enroll in chronic care management if ≥2 chronic conditions

— Patient portal activation, medication reconciliation, after-visit summary

— Physical activity: ≥150 min/week moderate or 75 min vigorous + 2 days resistance training

— Diet: Mediterranean or DASH pattern; reduce sodium <2300 mg/day, added sugar, processed meat

— Sleep: 7–9 hours

— Alcohol: ≤1 drink/day women, ≤2 men (US guidelines increasingly favor lower)

— Tobacco: complete cessation; nicotine and e-cigarettes included

Building the prevention "problem list" for longitudinal care:

Long-term pharmacotherapy initiated at the visit (typical "discharge" meds):

Immunization series to complete:

Care coordination orders:

Lifestyle prescriptions (written explicitly):

Step 3 management: When starting an ACEi, schedule a BMP in 1–2 weeks; a Cr rise ≤30% from baseline is acceptable and expected, not a reason to stop.

Board pearl: Document "discussed risks, benefits, and patient preference" for SDM items — this phrasing is what graders and auditors look for.

Follow-Up Cadence, Monitoring Parameters, and Outpatient Handoff

— 2 weeks: BMP if ACEi/ARB or diuretic started; BP recheck if pharmacotherapy initiated; med tolerance check

— 4–12 weeks: lipid panel after statin initiation; A1c trend after metformin

— 3 months: BP, A1c, weight, adherence; titrate therapy; PHQ-9 if on antidepressant

— 6 months: comprehensive chronic disease check; labs as indicated

— 12 months: next preventive visit / AWV; update screens, immunizations, family history

— Hypertension: HBPM diary; goal <130/80 for most adults

— Diabetes: A1c q3 mo until at goal, then q6 mo; annual eye, foot, urine albumin/Cr, lipid; dental q6 mo; foot self-exam

— Hyperlipidemia: lipid panel 4–12 wk after change, then 3–12 mo

— Osteoporosis on therapy: DEXA in 1–2 yr; check adherence, calcium/vit D, drug holiday after 5 yr oral bisphosphonate if low risk

— Tobacco cessation: phone follow-up at 1 wk and 1 mo post-quit date

— Depression: PHQ-9 at 4–6 wk after starting SSRI; full effect by 8–12 wk

— BP: annually if normal, more often if elevated

— Lipid: q4–6 yr if low risk

— A1c/glucose: q3 yr if normal in eligible adults

— Pap/HPV: q3 / q5 yr per modality

— Mammo: q2 yr 40–74

— Colonoscopy: q10 yr (normal); FIT annually

— DEXA: q2 yr if osteopenic, individualized if normal

— AAA: one-time

— LDCT: annually while eligible

— Summary of active problems, meds, allergies, recent screens with dates and results

— Pending tests with explicit responsibility

— Advance directive copy

Post-visit cadence (place these as scheduled orders on CCS):

Disease-specific monitoring:

Screening intervals (rapid reference):

Outpatient handoff (if patient is leaving the practice):

CCS pearl: On a wellness CCS case, schedule the next preventive visit at 12 months and intermediate disease-specific visits at appropriate intervals before ending the case — closing the loop scores well.

Step 3 management: After starting an SSRI, recheck in 2–4 weeks for suicidality and side effects, especially in adults <25.

Ethical, Legal, and Patient Safety Considerations

— Required for grade C recommendations: aspirin (40–59), PSA (55–69), CRC continuation (76–85), BRCA testing

— Document the conversation, alternatives, patient values, and chosen plan

— Use decision aids when available

— Adolescent confidentiality: minors can consent to STI testing/treatment, contraception, mental health, and substance use in most US states without parental notification; maintain confidentiality in stems

— HIV testing: opt-out is the federal standard — no separate written consent required

— Genetic testing: requires explicit informed consent and pre/post-test counseling; discuss GINA protections (employment, health insurance) and GINA gaps (life, disability, long-term care insurance)

— Reportable communicable diseases (HIV, TB, syphilis, GC, etc.) to public health

— Suspected child abuse, elder abuse, dependent adult abuse

— Certain injuries (gunshot, knife wounds in many states)

— Impaired drivers in selected states (especially seizures, dementia)

— IPV reporting laws vary — most states do not mandate; safety planning > forced reporting

— Spouses, parents of adults, and employers are not entitled to PHI without consent

— Use the patient portal carefully when family members share access

— Closed-loop test result communication: a positive screen with no follow-up is a sentinel safety event — document notification and next step

— Medication reconciliation at every preventive visit reduces ADEs

— Diagnostic error (missed cancer, missed MI presenting atypically) is the leading source of outpatient malpractice — pivot from screening to diagnostic when red flags appear

— Transitions of care: hospital → PCP within 7–14 days reduces readmissions; reconcile meds, reinforce red flags

— ACA mandates no cost-sharing for USPSTF A/B; help patients with uninsured screening through FQHCs, state programs (e.g., NBCCEDP for breast/cervical)

Shared decision-making (SDM) as an ethical obligation:

Informed consent edge cases on Step 3:

Mandatory reporting (must do, even over patient objection):

Confidentiality nuances:

Patient safety in the ambulatory setting:

Equity and access:

Board pearl: "Your duty to warn" (Tarasoff) and reportable diseases override confidentiality. IPV in competent adults generally does not mandate reporting — safety planning and resources are the correct answer.

High-Yield Associations and Rapid-Fire Clinical Facts

— 18: BP, lipids by 40 (earlier if risk), HIV once, HCV once, HBV once

— 21: cervical cytology start

— 26: HPV catch-up end (SDM 27–45)

— 35: diabetes screening start (overweight/obese)

— 40: ASCVD risk calc, mammography start (USPSTF 2024)

— 45: CRC screen start

— 50: LDCT start if ≥20 PY smoker, Shingrix

— 55: PSA SDM start

— 65: pneumococcal (PCV20 or PCV15+PPSV23), DEXA (women), AAA U/S (men 65–75 ever-smoker)

— 75: stop CRC routine; RSV universal

— 80: stop LDCT

— PSA ≥70

— Aspirin primary prevention ≥60

— Beta-carotene/vitamin E for CVD/cancer prevention

— Ovarian cancer screening

— Pancreatic cancer screening (average risk)

— Thyroid cancer screening

— Carotid artery stenosis screening

— Vitamin D for fall prevention in community-dwelling adults

— Routine COPD screening in asymptomatic adults

— Tdap each pregnancy 27–36 wk

— RSV in pregnancy 32–36 wk, Sept–Jan only

— Shingrix even if prior shingles or prior Zostavax

— PCV20 simplifies adult pneumococcal

— HPV 2-dose if started <15; 3-dose if ≥15 or immunocompromised

— ASCVD ≥7.5% → moderate-intensity statin

— FRAX ≥3% hip / ≥20% major → treat osteopenia

— STOP-BANG ≥3 → consider sleep study

— PHQ-9 ≥10 → treat depression

— AUDIT-C ≥4 (M) / ≥3 (F) → brief intervention

Age-triggered "do this now" list:

USPSTF grade D "don't order" landmines:

Vaccine quick hits:

Risk-factor catch-all numbers:

Preconception checklist mnemonic ("FAMILIES"): Folic acid, Alcohol/smoking cessation, Medications (teratogens), Immunizations, Labs (HIV/STI), Illness control (DM/HTN), Eating/exercise, Social support

Board pearl: When in doubt between two screening intervals, the less-aggressive USPSTF interval is usually the Step 3 answer over specialty society alternatives.

Board Question Stem Patterns

— Healthy 50-year-old man for routine visit: CRC screening, lipid panel, A1c (if overweight), HIV/HCV/HBV once, immunization review. Wrong answers: PSA without SDM, stress test, CXR, CBC

— Classic distractors: vitamin D level, TSH, PSA <55 or ≥70, CA-125, carotid duplex, routine EKG, urinalysis

— Stem slips in melena, breast mass, hemoptysis, or chest pain — answer pivots to diagnostic workup, not screening

— Borderline ASCVD 6%: CAC score is the right next step in many cases; statin if CAC ≥100

— Adult ≥60 asking about aspirin: do not start for primary prevention

— High-risk preeclampsia features (chronic HTN, prior preeclampsia, DM, CKD, autoimmune, multifetal): aspirin 81 mg from 12 wk

— Tdap timing: 27–36 wk each pregnancy

— 84-year-old with dementia, asks about colonoscopy: do not screen; discuss goals of care

— 16-year-old requests STI testing without parents knowing: provide confidential care

— Genetic testing offered: counseling first, GINA discussion

— 66-year-old never received pneumococcal: PCV20 once (preferred) or PCV15 then PPSV23 ≥1 yr later

— Immigrant adult unknown status: Tdap once + Td/Tdap q10y, MMR if non-immune, varicella, HBV, HPV if eligible, IGRA

— "Grade I" recommendations appear as distractors phrased as plausible orders — recognize and avoid (cognitive screening, oral cancer screen, etc.)

— Distinguishing AWV from comprehensive physical; ACA no-cost coverage of A/B services

Pattern 1 — "Most appropriate next step":

Pattern 2 — "Which test should NOT be ordered":

Pattern 3 — "Asymptomatic vs symptomatic":

Pattern 4 — Statin/aspirin SDM:

Pattern 5 — Pregnancy preventive:

Pattern 6 — Elderly with limited life expectancy:

Pattern 7 — Confidentiality/consent:

Pattern 8 — Vaccine selection:

Pattern 9 — USPSTF grade application:

Pattern 10 — Health systems/coding:

Board pearl: When two answers seem correct, choose the USPSTF grade A/B option over specialty society or grade C/I option unless the stem explicitly invokes the specialty guideline.

One-Line Recap

— Match age + risk to USPSTF: CRC at 45, diabetes 35–70 if overweight, mammo 40–74, LDCT 50–80 with ≥20 PY, AAA once in male ever-smokers 65–75, DEXA women ≥65, stop screens when life expectancy or age cutoffs say so

— Default to grade A/B and avoid grade D/I "junk orders" (vitamin D level, routine EKG, PSA ≥70, aspirin ≥60, ovarian/thyroid/pancreatic screens, carotid duplex in asymptomatic)

— SDM and document: PSA 55–69, aspirin 40–59 if ASCVD ≥10%, CRC 76–85, BRCA counseling, LDCT eligibility

— Always pivot on red flags: hematochezia → diagnostic colonoscopy; breast mass → diagnostic mammo + US; suicidal ideation → emergent psych; BP ≥180/120 with end-organ → ED

— Close the loop on CCS: order screens, advance the clock to results, place named referrals (RD, DPP, GI, derm, cardiology), reconcile medications, schedule 2-week, 3-month, and 12-month follow-ups

Bottom line: A Step 3 CCS preventive visit is won by efficiently delivering age- and risk-appropriate USPSTF grade A/B screening, ACIP-recommended immunizations, behavioral counseling, and SDM-anchored chemoprevention, while pivoting to diagnostic workup whenever red flags appear and scheduling explicit, time-anchored follow-up.

Five-bullet recap to walk into the test with:

CCS pearl: End every wellness case by scheduling the next AWV at 12 months, completing immunization series with explicit return dates, and confirming closed-loop communication of all results — the simulator (and real-world practice) rewards completeness over volume.

Board pearl: The single highest-yield mental model is "asymptomatic adult + USPSTF grade letter → action." Master the grades and the age triggers, and you will out-score classmates relying on memorized lists.